Trump Team Said to Consider Thiel Associate O’Neill for FDA
- Jim O’Neill is a managing director at Thiel’s Mithril Capital
- In speech, said FDA could approve drugs without efficacy data
Peter Thiel, co-founder of PayPal Inc., speaks during a news conference at the National Press Club in Washington on Oct. 31, 2016.
Photographer: Andrew Harrer/BloombergThis article is for subscribers only.
President-elect Donald Trump’s transition team is considering a Silicon Valley investor close to billionaire Peter Thiel to head the Food and Drug Administration, according to people familiar with the matter.
Jim O’Neill, the Thiel associate, hasn’t been officially selected, according to the people, who asked to remain anonymous because the decision process is private, and the Trump team could still go in another direction.